Celltrion and Teva’s Rituximab Biosimilar Gains FDA Approval

Drug Industry Daily
A A
The FDA announced the first biosimilar of Roche’s blockbuster cancer drug Rituxan (rituximab) — approving Teva and Celltrion’s Truxima (rituximab-abbs) for treating non-Hodgkin’s lymphoma.

To View This Article:

Login

Subscribe To Drug Industry Daily